[O-35] 一般演題口演セッション35

[O-35-2] FIREFISH：脊髄性筋萎縮症I型患者のリスジプラム3年投与時の有効性・安全性

^○竹島 泰弘¹, Riccardo Masson², Maria Mazurkiewiczbeldzinska³, Kristy Rose⁴, Laurent Servais⁵, Hui Xiong⁶, Edmar Zanoteli⁷, Muna El-khairi⁸, Marianne Gerber⁹, Ksenija Gorni⁹, Heidemarie Kletzl⁹, Angela Dodman⁹, Eleni Gaki⁸, Basil T Darras¹⁰ (1.兵庫医科大学病院 小児科, 2.Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, 3.Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, 4.Department of Developmental Neurology, Medical University of Gdansk, Gdansk, Poland, 5.Paediatric Gait Analysis Service of New South Wales, The Children’s Hospital at Westmead, Sydney, Australia, 6.I-Motion - Hopital Armand Trousseau, Paris, France, 7.Department of Pediatrics, Peking University First Hospital, Beijing, China, 8.Department of Neurology, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil;, 9.Roche Products Ltd, Welwyn Garden City, UK, 10.F. Hoffmann-La Roche Ltd, Basel, Switzerland)